mikesassa

[mikesassa]

Thailand has over 12,000 licensed dispensaries, not including untold numbers of unlicensed vendors. California, which had nearly 3,000 unlicensed dispensaries at the start of its adult-use cannabis market and thousands in New York City within months of decriminalization, comparably pales to Thailand’s growth.

It is difficult to compare the dominance of unlicensed dispensaries in such Western markets to Thailand’s mostly licensed legal infrastructure. Potentially, this system is about to be shaken up with rumors of a strict medical market incoming. However, once you set foot in Thailand, it is almost impossible to imagine American or European-style medical or recreational models finding success, for that matter. Why? Because cannabis is everywhere!

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

The Australian medical cannabis industry may have its challenges, but its focus on affordable access and patient care make it a role model for the rest of the world, says SOMAÍ Pharmaceuticals chairman and CEO Michael Sassano.

The Australian market has become one of only three significant global medical cannabis markets in the world. 

Although all eyes are on the US potentially rescheduling the substance after Germany removed the narcotics label from cannabis medicines, the Australian market continues to expand faster than most because of the focus on what is best for patients and their experience.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

You may not see it or even hear about it but have no doubts: an enormous regulatory framework tsunami pushing global medical cannabis is happening right now. 

In the first two months of 2024, two significant catalytic events occurred, the likes of which have not been seen since California first went recreational in 2016, starting the United States’ industrial cannabis boom. Germany, the largest and most powerful country in Europe, decriminalized cannabis and, most importantly, took cannabis off the narcotics registry.

Additionally, a top U.S. health organization — the Health and Human Services (HHS) — wrote a recommendation letter and corresponding 252-page report to the Drug Enforcement Agency (DEA) after two decades of observing medical and recreational cannabis, concluding that not only is cannabis safe but further acknowledging cannabis is effective for at “least” 15 medical indications including neuropathic pain.

#biotechnology #medical cannabis #manufacturing #cannabismarket #cannabisnews #cannabis #cannabiseu #cannabisindustry #cannabisleaders #pharmtech

[mikesassa]

European medicinal cannabis manufacturing powerhouse SOMAÍ Pharmaceuticals is set to shake up the Australian market with a range of products designed to create new standards in the quality and variety of cannabinoid medicine.

The Portugal-based company, which operates a 3,800 square metre, state-of-the-art manufacturing facility and 2,500sqm indoor cultivation facility boasting Cookies genetics and non-irradiated material, has identified the Australian market entry as the key pillar of its international expansion strategy.

#cannabis #biotechnology #manufacturing #cannabisnews #cannabisleaders #cannabismarket #medical cannabis #pharmtech #cannabiseu #cannabisindustry

[mikesassa]

Now that Ukrainian President Volodymyr Zelenskiy has signed a law opening access to medical cannabis, Ukraine has joined a list of emerging countries that recognize the benefits of this plant for their people, writes Michael Sassano, CEO and founder of SOMAÍ Pharmaceuticals.

#cannabis #medical cannabis #cannabisindustry #cannabismarket #manufacturing #cannabiseu #cannabisnews #cannabisleaders #biotechnology #pharmtech

[mikesassa]

As 2023 ended, all eyes remained glued on the United States Schedule III and German narcotics derivation re-listing, the latter of which successfully passed at the end of February 2024.

A Q3 event worth noting was in August 2023, when the U.S. Health and Human Services (HHS) recommendation letter and 252-page supporting report were released through the Freedom of Information Act and ignited a storm as the most knowledgeable agency watching cannabis for the last two decades in the U.S. essentially acknowledged that cannabis is both safe for the population and has medicinal attributes that help “at least 15 medical conditions” and is a safer alternative to drugs currently on the market.

Both events, in conjunction or individually, remain the most active topics in the global cannabis markets. Although policy shifts are difficult to predict, taken together, they will likely cause a worldwide rescheduling of cannabis that will run from country to country and require World Health Organization (WHO) consideration.

#cannabis #medical cannabis #biotechnology #cannabismarket #manufacturing #cannabiseu #cannabisnews #cannabisleaders #cannabisindustry #pharmtech

[mikesassa]

As Hop Latent Viroid is discovered in Australian cannabis crops for the first time, SOMAÍ Pharmaceuticals founder, chairman, and CEO Michael Sassano shares advice for any growers struck down by the potentially costly problem in Cannabiz.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

Recently, I have become more optimistic about the global landscape of medical cannabis and the direction in which major regulatory agencies are heading. Years of stifling regulatory environments and political headwinds that have hampered the cannabis industry seem to be giving way to real progress.

Earlier this year, the United States Department of Health and Human Services (HHS) released a 252-page report stating that cannabis is safe. The health authority further noted that cannabis has true potential as a medicine that can help with symptomatic conditions for at least 15 medical indications. After decades of assertions that there is not enough evidence cannabis is safe and valuable as a medicine, this news is truly transformational for the industry.

Most reading this article have always known this. However, many people believed these hostile, politically motivated, and biased authorities were blocking hundreds of millions of people from access to safer medications. This publication from the HHS could and should herald a major shift.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabisnews #cannabismarket #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

"As the entire cannabis world is abuzz and cannabis stocks are shooting through the roof with the potential United States rescheduling of cannabis to Schedule III and Germany likely rescheduling cannabis off the narcotics list, forecasters are looking beyond the major markets of U.S., Canada and even past global cannabis market leaders like Germany, Australia and to some extent the United Kingdom," in the latest article in Benzinga, Michael Sassano discusses the rapidly growing global cannabis markets anticipated in 2024, highlighting emerging countries like Switzerland, Czechia, Brazil, Thailand, Ukraine, and Spain.

#cannabis #biotechnology #medical cannabis #manufacturing #cannabisindustry #cannabisnews #cannabismarket #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

"Extractors worldwide constantly innovate product lines to reach their customers and patients better. What I describe as the “golden triangle” – or core components for these adventurous formulators to create a winning product – is taste, effect, and pricing (TEP). Although the weighting of these factors may differ for each producer, one thing never changes when tapping into the market with new extract products – nobody wants to take something daily that tastes bad," Michael Sassano invites you to dive deeper into addressing consumer taste concerns via purposeful formulation.

#cannabis #medical cannabis #biotechnology #manufacturing #cannabisindustry #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

On January 12, the United States Department of Health and Human Services (HHS) released a letter and supporting 252-page document that will make it extremely difficult for the Drug Enforcement Agency (DEA) to ignore its findings on the benefits of cannabis and all but ensuring that the U.S. will reschedule cannabis from current listing as a Schedule I to a Schedule III drug.

However, the biggest ramification for the global medicinal cannabis market is that every regulator in every country woke up to the most influential regulator on earth telling the world that cannabis is both safe and indeed is a medicine that treats at least 15 ailments, especially pain.

#cannabis #medical cannabis #cannabisindustry #biotechnology #manufacturing #cannabisnews #cannabismarket #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

Cannabis has long been trending as a global product, providing regional players with the chance to expand into international markets. Somai Pharmaceuticals founder, chairman and CEO Michael Sassano explores the opportunities for Australian firms.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabisnews #cannabismarket #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

Year after year, global cannabis revenues exceed expectations and now stand at an estimated $50 billion in global sales in 2023. If you add in the illicit market, the number could be more like $344 billion, and this does not even take into account new demographics that will open as legalization increases, as it’s already the most-used drug worldwide while still being illegal in most countries. 

2024 is shaping up to be a year of potential big wins for cannabis from legislative, valuative, and popular opinion viewpoints.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabisnews #cannabismarket #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

According to Michael Sassano, the end result of this operation will be “one of the few vertical cannabis companies in the EU, with indoor and greenhouse cultivation capabilities, the most advanced manufacturing products in all global markets, as well as distribution in Australia and Germany, the global markets numbers one and two, as well as sales channels in the United Kingdom and Poland.” Furthermore, Michael says that “as newer countries show more progress, we will bring the broadest range of products to these emerging markets.”

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

"2024 is shaping up to be a year of potential big wins for cannabis from legislative, valuative, and popular opinion viewpoints. Clearly, politics and regulations have always been an Achilles heel for cannabis. Recent movements show that regulators are rejecting political lobbyists and going for what is right and popular," shares SOMAÍ's Founder and CEO Michael Sassano with the Business of Cannabis.

#cannabis #biotechnology #medical cannabis #manufacturing #cannabisindustry #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech

[mikesassa]

Year over year, global cannabis revenues exceed expectations and now stand at an estimated $50 billion in global sales in 2023. If you add in the illicit market, the number could be more like $344 billion, and this does not even take into account new demographics that will open as legalization increases, as it’s already the most-used drug worldwide while still being illegal in most countries. 

2024 is shaping up to be a year of potential big wins for cannabis from legislative, valuative, and popular opinion viewpoints.

#cannabis #cannabisleaders #cannabisnews #pharmtech #cannabiseu #cannabismarket #manufacturing #biotechnology #medical cannabis #cannabisindustry

[mikesassa]

As Switzerland opens up its first cannabis dispensary, cannabis pharmacies in the European Union need to pay attention and look to the future.

The cannabis market in Europe has been changing for almost two decades, and U.S.-style dispensaries are now a reality in the EU. Regulators from around the globe have visited U.S. and Canadian dispensaries, and Germany has announced the second pillar of their program will be a dispensary model. If the EU truly wants to combat the illicit market, dispensaries are the way forward.

#cannabis #medical cannabis #biotechnology #cannabisindustry #manufacturing #cannabismarket #cannabisnews #cannabiseu #cannabisleaders #pharmtech